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ABSTRACT 
 
Ganesan, Ramya. M.S. Department of Microbiology and Immunology, Wright State University, 
2013. Site of Action of Inhibitors of PLD2 and the Role of Interacting Partners of PLD2 during 
Inhibition. 
	  
Phospholipase D (PLD) is a key enzyme for the remodeling of phospholipids in the cell 
membrane. PLD has been implicated in many physiological functions such as chemotaxis 
and phagocytosis as well as pathological functions such as ischemia/reperfusion and 
cancer metastasis. Several small molecule inhibitors of PLD have been recently 
developed to overcome these pathological effects. We have concentrated on 5-Fluoro-2-
Indolyl des-Chlorohalopemide (FIPI) which is an indole derivative of halopemide that 
inhibits the two mammalian isoforms PLD1 and PLD2. We also concentrate on N-[2-[1-
(3-Fluorophenyl)-4-oxo-1,3,-8-triazaspiro[4.5]dec-8-yl]ethyl]-2-naphthalenecarboxamide 
(NFOT) and N-[2-(4-oxo-1-phenyl-1,3,8-triazaspiro[4,5]dec-8-yl)ethyl]-2-
naphthalenecarboxamide (NOPT) that are specific inhibitors of the PLD2 isoform. In 
spite of knowing their specificity derived from in vitro assays, the mechanism of action 
of these inhibitors has never been studied.  Here for the first time, we show the site of 
action of FIPI and NFOT on PLD as well as a mechanism of enzymatic action that 
explains in vivo actions. Our studies showed that FIPI is a non-reversible inhibitor of 
PLD that binds to the HKD, whereas NFOT shows mixed type of inhibition, which 
suggests that inhibitor binding site might be anywhere in the regulatory PX or PH 
domains of PLD2 or the catalytic region HKD. We performed extensive mutational 
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analysis on PLD2 and our results clearly indicate that FIPI binds to S757 residue and 
S648 and a PIP2 binding site are critical for NFOT to inhibit PLD2, since mutating these 
key amino acid(s) resulted in partial resistance of the enzyme towards the inhibitor. 
Inhibitor dose dependent assays of the resistant PLD2 mutants F244N/L245A/L246A and 
S648A confirmed the same.  Also, the mutants exhibited resistance against the inhibitors 
unlike wild-type, in performing chemotaxis further confirming physiological relevance. 
In addition, we uncovered the effect of PLD2 binding partners, Grb2 and Ras on the 
efficacy of inhibitors. Mechanistically it was found that Grb2 positively regulates PLD2, 
while Ras has a negative effect on PLD2 and that the small molecule inhibitor’s action on 
PLD2 is affected by the absence or presence of Grb2 or Ras. In conclusion, we consider 
the results obtained in this study regarding the key residues of PLD2 are crucial in order 
to develop more potent and efficient inhibitors that can be used in vivo for pathological 
processes such as chronic inflammation and cancer metastasis. 
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HYPOTHESIS AND SPECIFIC AIMS 
Hypothesis: 
It is hypothesized that one or more amino acids in either the regulatory PX and/or PH 
domains or within or in the near vicinity of the catalytic site is essential for the action of 
inhibitors on PLD2 and that mutating these key amino acid(s) will result in resistance of 
the enzyme towards the inhibitor. In addition, the inhibitor’s action on PLD2 is effected 
by the presence or absence of protein interacting partners of PLD2. 
Specific aims: The hypothesis will be tested by three different specific aims. 
Aim1: To determine the nature of the PLD inhibitors: reversible or irreversible  
Aim2: To determine the site of action of PLD inhibitors on PLD by screening for mutants 
in the PX, PH and around the HKD motif and study biological relevance of these mutated 
sites 
Aim3: To determine the role of interacting proteins in preserving PLD from PLD 
inhibitors 
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INTRODUCTION 
Phospholipase D (PLD) is a hydrolytic enzyme present in the cell membrane that 
catalyzes the conversion of phospholipid namely phosphocholine (PC) to produce free 
acid, phosphatidic acid (PA) (Fig 1). PA is involved in cellular signaling and membrane 
dynamics in all eukaryotes (Kooijman and Burger 2009). Phospholipase D belongs to the 
HKD superfamily, and as the name suggests PLD has “HxKxxDxxxx” motif in its 
catalytic site. This HKD motif accounts for the lipase activity of Phospholipase D. There 
are 6 isoforms of mammalian PLD, namely PLD1-6 (Fig 3). PLD1 and PLD2 belong to 
the classical HKD superfamily that possesses phosphoinositide binding (PX) and 
pleckstrin homology (PH) domains with 2 HKD motifs, while PLD3-6, cardiolipin 
synthase, etc. belong to the non-classical HKD superfamily that lack PX and PH domains 
and may have 1 or 2 HKD motifs. The PX and PH domains of PLD are the regulatory 
domains of PLD. 
  PLD is implicated in many physiological and pathological functions in cells. 
Apart from its lipase activity, PLD interacts with proteins such as Rac2, Grb2-SOS, 
WASp, S6K (Di Fulvio, Lehman et al. 2006; Lehman, Ledford et al. 2007; Kantonen, 
Hatton et al. 2011; Peng, Henkels et al. 2011) and Bcl-2 and performs functions such as 
chemotaxis, cell migration, DNA synthesis and anti-apoptosis (Banno 2002). Of all the 6 
known mammalian PLD isoforms, PLD1 and PLD2 are well studied. PLD2 is 
constitutively active, unlike PLD1. Importantly dysregulation of PLD2 can result in 
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pathological conditions such as cancer metastasis, cell invasion and chronic 
inflammation. Hence it is important to have PLD2 inhibitors to protect cells from the 
pathological implications of PLD2. A number of PLD inhibitors have been developed so 
far. Some of the classical PLD inhibitors are ethanol and butanol. Due to some off target 
effects and non-specificity of these primary alcohols, other serine protease inhibitors 
were used to inhibit PLD.  
Halopemides, that were used as neuroleptic agents have been identified as PLD 
inhibitors. Recently, specific small molecule inhibitors of PLD (Table 1) have been 
developed including N-[2-[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-
piperidinyl]ethyl]-5-fluoro-1H-indole-2-carboxamide (FIPI), N-[2-(4-oxo-1-phenyl-1,3,
8-triazaspiro[4,5]dec-8-yl)ethyl]-2-naphthalenecarboxamide (NOPT) and N-[2-[1-(3-
Fluorophenyl)-4-oxo-1,3,8-triazaspiro[4.5]dec-8-yl]ethyl]-2-naphthalenecarboxamide 
(NFOT), N-[2-[4-(5-chloro-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]-1-
methylethyl]-2-naphthalenecarboxamide (809), (1R,2R)-N-([S]-1-{4-[5-bromo-2-oxo-
2,3-dihydro-1H-benzo(d)imidazol-1-yl]piperidin-1-yl}propan-2-yl)-2- 
phenylcyclopropanecarboxamide (NBOD) and Apigenin (Scott, Selvy et al. 2009; Su, 
Chen et al. 2009; Lavieri, Scott et al. 2010). These inhibitors show greater inhibition in 
vitro, while in vivo they are not bio-assimilated and hence reduced bio-availability occurs 
despite using very micromolar concentrations of inhibitors.  
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Recently our lab showed that PLD2 is involved in tumor metastasis and invasion. 
Some of the specific small molecule inhibitors of PLD such as Apigenin, FIPI and NOPT 
inhibit tumor metastasis and cell invasion in mice models (Henkels, Boivin et al. 2013). 
To date there is no clear site of action of these specific small molecule inhibitors on 
PLD2 and the mechanism of action of these inhibitors on PLD is not known. 
This study is the first determination of the site of action of three small molecule inhibitors 
on PLD. The importance of this is that knowledge about the mechanism and kinetics of 
the existing inhibitors will help in developing more potent PLD inhibitors to be used in 
pathological conditions.  
This study shows that the site of action of the specific PLD2 inhibitor NFOT is 
serine 648, while the dual PLD inhibitor FIPI is serine 757, which is partly confirmed by 
enzyme competition assays showing mixed inhibition wherein, FIPI covalently modifies 
PLD2 and NFOT binds the regulatory domains of PLD2. Since, in vivo conditions PLD2 
is surrounded by its binding protein partners, we also studied the influence of PLD2 
binding partners, Grb2 and Ras on the effect of inhibitors. We found that these critically 
regulate PLD2 inhibition. Grb2 acts as a positive effector of lipase activity protecting 
sites for inhibitor binding, while Ras acts as a positive effector of lipase activity of PLD2 
at low concentrations and does not affect inhibition as concentration increases. Grb2 
increases the IC50 of FIPI for PLD2 negatively regulates the inhibitor action. 
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LITERATURE REVIEW AND PRELIMINARY DATA 
Enzymatic role of Phopholipase D 
Phospholipase D (PLD), as the name indicates is a lipase that hydrolyzes 
phospholipids such as phosphatidylcholine (PC) to produce a phosphatidic acid (PA) and 
a soluble choline head group. In the presence of primary alcohol such as butanol, PLD 
hydrolyzes phosphatidyl choline producing phosphatidylbutanol by a biochemical 
process named transphosphatidylation. This catalytic reaction of PLD with butanol 
enables the measurement of in vitro PLD activity assay by inducing radiolabelled [3H]- 
butanol which yields a product [3H]- phosphatidylbutanol. This product is not 
metabolically changed any further and can be quantified in a scintillation counter after 
lipid extraction and chromatographic separation. 
Phospholipase D: its structure and function 
Phospholipase D is normally present in the cell membrane, but also localized in 
perinuclear and golgi membranes as well.  There are mainly six isoforms of PLD namely 
PLD1-6. PLD protein PLD belongs to the HKD superfamily. The majority of members in 
this superfamily contain a short conserved sequence motif (H-x-K-x(4)-D), where x 
represents any amino acid residue), called the “HKD signature motif”. It consists of a 
histidine, a lysine and an aspartic acid in close proximity; normally a classical PLD 
molecule bears two HKD domains for full enzymatic activity.	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Mammalian PLD1 and PLD2 belong to the classical HKD superfamily (Fig 2) 
that possesses phosphoinositide binding (PX) and pleckstrin homology (PH) domains 
with 2 HKD motifs, while PLD3-6, cardiolipin synthase and some endonuclease belong 
to the non-classical HKD superfamily that lack PX and PH domains and may have 1 or 2 
HKD motifs. The PX and PH domains of PLD are the regulatory domains of PLD. The 
PX is a phosphointositide binding domain involved in targeting of proteins to cell 
membranes. The PX domain was first identified in P40phox and p47phox of NADPH 
oxidase and later was also found in many PI3 kinases (Ponting 1996; Wishart, Taylor et 
al. 2001). Phox is an abbreviation for phagocytic oxidase.  
The PH domain is approximately 120 amino acid sequence that occurs in many 
proteins that are involved in signaling or are constituents of cytoskeleton. This domain 
can bind PI lipids within the membrane (Wang and Shaw 1995), βγ subunits of 
heterotrimeric G proteins such as receptor tyrosine and serine/threonine kinases (Wang, 
Shaw et al. 1994) and protein kinase C (Yao, Kawakami et al. 1994). 
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Fig 1. PLD activity. Schematic representation of lipase activity showing hydrolysis and 
transphosphatidylation reactions catalyzed by PLD 
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Fig 2. HKD Superfamily. The members of the HKD family are classified into classical 
and non-classical PLDs. The classical PLDs have PX and PH regulatory domains, while 
non-classical lack PX and PH domains. 
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Fig 3. Isoforms of PLD, their structure and functions  
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  PLD: Mechanism of action 
Most PLD enzymes are monomeric proteins that possess two HKD-motif containing 
domains. These two HKD motifs from two such domains form a single active site. PLD6 
in mitochondria has only one HKD motif per subunit but form an active dimer, which has 
a single active site at the dimer interface containing the two HKD motifs from both 
subunits. Despite differenced in catalytic functions and a very broad range of substrate 
specificities, the diverse group of PLD enzymes bind to and attack a phosphodiester 
moiety. Most of them are known to possess structurally similar active sites and thought to 
utilize a common two-step ping-pong catalytic mechanism, involving an enzyme-
substrate intermediate, to cleave phosphodiester bonds.  
Two-step mechanism (Fig 4): 
1) The imidazole group of histidine in the HKD motif is a nucleophile that attacks 
the phosphate group of the substrate PC. A covalent bond is formed between the 
phosphate and the histidine generating a phosphatidyl-histidine intermediate. 
This is the rate limiting step. 
2) In the second step, water or hydroxyl from an alcohol (eg. Butanol) 
nucleophilically attacks the phosphate in the intermediate releasing PA (or a 
phosphatidyl-alcohol) as the free enzyme. 
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Fig 4. Schematic of a two-step mechanism of action of PLD 
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Mammalian PLD structure and sequence alignment 
PLD1 and 2 are the mammalian isoforms of PLD. PLD1 and PLD2 share ~50% 
homology. Two HKD motifs are necessary for their enzymatic activities. They possess 
the PX and PH regulatory domains (Fig 5).  
The gene encoding PLD1 is on chromosome 3q.26 (human) and encodes a protein 
of ~120 KDa protein. PLD1 has many splice variants such as a, b, a2, b2. PLD1a is the 
longest of the splice variants and is 1074 amino acids long. Subcellularly PLD1 is 
localized in golgi, endoplasmic reticulum and endosomes. PLD1 requires small GTPases 
such as Arf, Rho and protein kinase C (PKC) and phosphatidyl inositol 4,5 bis phosphate 
(PIP2) for its activation.  
PLD2 gene is on chromosome 17p.13 (human). PLD1 is longer than PLD2 due to 
the presence of a “loop” in the protein and hence its molecular weight is 105 KDa. Splice 
variants of PLD2 are PLD2a, b and c. PLD2a is the longest with 933 aminoacids. PLD2 
localizes at cell membrane as well as cytosol. PLD2 requires only PIP2 and minimally 
PKC for its activity. PLD2 is constitutively active while PLD1 is not. Nevertheless, both 
isoforms are activated by cell agonists such as growth factors 
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Fig 5. PLD1 and PLD2 protein. PLD protein structures showing the difference 
between the two mammalian isoforms PLD1 and PLD2. (Gomez-Cambronero 2011) 
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Physiological functions of PLD 
PLD plays a major role in various physiological processes, including cell migration, 
phagocytosis (Kantonen, Hatton et al. 2011), chemotaxis (Lehman, Ledford et al. 2007), 
DNA synthesis (Di Fulvio, Lehman et al. 2006), membrane vesicle trafficking, actin 
cytoskeleton remodeling, membrane ruffling (Mahankali, Peng et al. 2011), cell growth 
and survival, anti-apoptosis (Oh, Lee et al. 2007) and also pathological conditions such as 
cancer cell metastasis, tumor progression (Henkels, Boivin et al. 2013) and inflammation 
(Peng, Henkels et al. 2011). PLD1 is essential for basal chemokinesis, while PLD2 is 
constitutively active. 
PA as produced from PLD is a major lipid second messenger that is involved in 
several intracellular signaling pathways. Few of the pathways where PA is key player are 
described below. For example, PA initiates a signal cascade that results in PA binding to 
ribosomal S6 kinase (S6K) and subsequent actin polymerization and chemotaxis, wherein 
PA acts as a chemoattractant for leukocytes (Lehman, Ledford et al. 2007). PA interacts 
with many other proteins such as mTOR, Sos (Zhao, Du et al. 2007), Rac and Ras (Peng, 
Henkels et al. 2011) subsequently causing actin polymerization followed by cell 
migration or chemotaxis in normal as well as cancer cells. PA also interacts with Sos 
through Grb2 activating the Erk/MAPK pathway culminating in DNA synthesis (Di 
Fulvio, Lehman et al. 2006). PA functions in cellular signaling pathways as a direct lipid 
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second messenger or as an indirect precursor, once converted to other bioactive lipids 
such as LPA and DAG. 
 PA is essential for activating mTORC in mTOR, the protein involved in cell 
cycle progression and cell growth. p70S6 Kinase which is a downstream target of mTOR 
is activated by phosphorylation results in phosphorylation of the S6 protein resulting in 
protein synthesis (Fang, Vilella-Bach et al. 2001). PA also activates S6 independent of 
mTOR. PA is also involved in cell survival and anti-apoptosis via interactions with Bcl-2 
and Bcl-xl (Oh, Lee et al. 2007). PA generated by PLD2 plays an important role in cell 
survival during Fas-mediated apoptosis through the increased Bcl-2 and Bcl-xL protein 
levels which resulted from PLA2 and AA-COX2 pathway (Kang, Jang et al. 1998). 
Pathological role of PLD 
PLD is involved in inflammation and cancer invasion or metastasis. A study showed that 
cancer cell invasiveness is dependent on the presence of PLD2 at the time of metastatic 
initiation. Recent studies have shown that PLD2 activity is regulated by phosphorylation 
and dephosphorylation. Three kinases EGFR, Src and JAK3 are found to phosphorylate 
PLD2 at specific tyrosine residues 296, 511 and 415 respectively. Y296 phosphorylation 
showed an inhibitory effect while that of Y415 showed activation functions. Also 
phosphorylation of Y511 is either activational or inhibitory depending on the cell-type. A 
high level of cell invasiveness of cancer cells was shown by a combined high 
JAK3/PLD2 phosphorylation and activity, involving PLD2’s Y415 residue (Henkels, 
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Peng et al. 2010). In COS7s prominent phosphorylation by JAK3 on Y415 activation site 
and moderate phosphorylation by EGFR kinase and Src on Y296 and Y511, led to great 
PLD2 activity. This study shows that importance of PLD2 activity in cancer by 
highlighting the regulation of phosphorylation-dephosphorylation of PLD2. In the low 
invasive breast cancer MCF-7s it was shown that phosphorylation of the inhibitory Y296 
in PLD2 by EGFR kinase stimulation is a reason for low PLD activity in MCF-7s than 
aggressive MDA-MB-231s and normal COS7s.  
PLD binds to Grb2 via phosphorylated Y169 and Y179 residues and recruits Sos, 
while PLD-derived PA directly binds to Sos, both ultimately promote GTP loading of 
Ras and stimulates the MEK/ERK pathways (Zhao, Du et al. 2007). The stimulation of 
MEK/ERK pathway results in cell proliferation and transformation. PLD has been 
implicated in colorectal cancer, wherein high level of PLD2 expression was observed in 
patients with colorectal cancer (Oshimoto, Okamura et al. 2003).  
Another study in Japan involved studying a polymorphism in PLD2 1814 C à T 
causing a mutation, Ile577Thr was predominant in colorectal cancer patients, but this 
polymorphism did not affect PLD activity (Yamada, Hamajima et al. 2003). In yet 
another study, 97 colon carcinoma samples were tested for PLD2 levels and it was 
observed that there was high PLD2 level in the tumor samples. The PLD2 levels varied 
between tumors but were relative to tumor size (Saito, Ohata et al. 2007). 
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 In a recent study, it has been shown that PLD2 is very critical in cancer 
invasiveness and metastasis. It was shown that by subjecting SCID mice that have been 
injected with human breast cancer cells alone or human breast cancer cells silenced for 
PLD2, were also given PLD inhibitors at a fixed dose/mg/Kg/day. It was observed that 
tumor growth was inhibited significantly in the mice that were given PLD inhibitors. 
Also the mice that were silenced for PLD2 inhibited metastasis to a great extent 
(Henkels, Boivin et al. 2013). Similar studies have also shown that PLD1 plays a major 
role in tumor invasion and metastasis.  
Protein interacting partners of PLD2 
PLD2 interacts with several protein partners such as Grb2, Ras, Rac, WASp, Sos and 
S6K. 
The proteins of interest for this study are Grb2 and Ras, the details of which are described 
below. 
i) Grb2 and its interaction with PLD2 
The Growth factor receptor-bound protein 2 (Grb2) is an adaptor protein involved in 
signal transduction. Grb2 has one SH2 domain and two SH3 domains. Its SH3 domains 
mediate complex formation with proline-rich residues, while SH2 domain interacts with 
phosphorylated tyrosine residues in target proteins such as EGFR and PDGFR 
(Lowenstein, Daly et al. 1992). Grb2 is a crucial protein for cell cycle progression and for 
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actin based cell motility. It is also involved in other complex processes such as 
angiogenesis, epithelial morphogenesis and vasculogenesis (Giubellino, Burke et al. 
2008). Grb2 is involved in many cellular processes essential for cell survival, growth and 
proliferation. It translocates to the plasma membrane when activated by EGF and binds to 
EGFR through the phosphotyrosine containing proteins on its SH2 domains (Yu, Chen et 
al. 2008). Activation of Ras-guanine nucleotide exchange factor, Sos by interaction of 
SH3 of Grb2 with C-terminal Proline-rich regions in Ras and Sos is a well characterized 
mechanism that results in the activation of MAPK cascade and cell proliferation 
(Chardin, Camonis et al. 1993; Egan, Giddings et al. 1993). 
The SH2 domain of Grb2 also serves the recruitment of phosphotyrosine motif 
pYxN located on the PH domain of PLD2 (Schlessinger 1994). PH domain of PLD2 
binds to the SH2/SH3 containing tyrosine kinases (Ahn, Oh et al. 2003; Choi, Hiragun et 
al. 2004) and an increase in PLD activity correlates with increase in the overall tyrosine 
phosphorylation of PLD2 (Choi, Hiragun et al. 2004). PLD binds to Grb2 and recruits 
Sos, while PLD-derived PA directly binds to Sos, both ultimately promote GTP loading 
of Ras and stimulates the MEK/ERK pathways (Zhao, Du et al. 2007). PX residues of 
PLD2 Y169 and Y179 are necessary for binding to Grb2 and recruiting Sos, wherein Y169 
modulates enzyme activity while Y179 is essential for tyrosine phosphorylation of the 
protein (Di Fulvio, Frondorf et al. 2007).  
	   	   18	  
	   	   	   	  
Also, Y511 is shown to be involved in tyrosine interactions between PLD2 and 
Grb2. When Y179 and Y511 are phosphorylated, they mediate enzyme phosphorylation 
and thus activate PLD2-Grb2 interaction mediating lipase activity, while on the other 
hand when they are unphosphorylated, the PLD2 activity decreases and signals for cell 
proliferation and de novo DNA synthesis (Henkels, Short et al. 2009). Since we know 
that Grb2 interacts with Y169/179 of PLD2 through its SH2 domains, we are interested to 
know if this Grb2 interaction with PLD2 affects the binding and action of small molecule 
PLD2 inhibitors. 
ii) PLD2 and Ras 
Ras is a small G protein that has GTPase activity and involved in intracellular signaling. 
Ras is a member of the Ras family of proteins that also include Rad, Rab, Rap, Ran, Rho, 
Rheb, Rit, and Arf. PLD2 is known to activate Ras via PA production. PA interacts with 
PH domain of Sos and thus stimulates Sos mechanisms to activate Ras while coupling 
Ras activation with extracellular EGFR signaling (Zhao, Du et al. 2007). Another study 
shows that PLD2 regulates Ras-GEF, Ras-GRF1 in response to intergrin, wherein PLD2 
recruits RasGRF1 to the plasma membrane to activate Ras (Mor, Campi et al. 2007). 
On the other hand, PLD activity is elevated by oncogenic stimulus via H-Ras and 
not V-Ras. H-Ras localizing in caveolin rich membrane fractions elevates PLD activity 
by stimulating the activity of Arf6 and RalA (Xu, Frankel et al. 2003). Earlier studies 
show that v-src activates PLD activity by G-proteins (Jiang, Alexandropoulos et al. 
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1994). These studies were followed by another study which states that v-src induced PLD 
activity is Ras mediated by providivg three lines of evidence. First of which shows that in 
v-src transformed Balb/c 3T3 cells, PLD activity reduces by the use of neutralizing Ras 
monoclonal antibodies.  
Secondly immobilized Ras protein tired cytosolic ability to stimulate PLD 
activity. Lastly expression of Ras negative mutant in v-src transformed cells reduced 
PLD activity levels to that of nontransformed cells (Jiang, Lu et al. 1995). Recent 
findings have shown that PLD2 acts as a GEF on Ras, wherein it has been shown that Ras 
is a better substrate for PLD2-GEF following faster kinetics than any other GTPase such 
as Rac2 or Rac1. The study showed that in the absence of PLD2-GEF cell growth and 
proliferation was affected and that PLD2 by itself is involved in Ras activation and not by 
its product PA (Henkels, Mahankali et al. 2013). 
PLD inhibitors 
Inhibitors of Phospholipase D, are molecules that inhibit the enzymatic activity of PLD 
by interacting at specific sites on PLD preventing it from converting PC to PA thus the 
downstream processes. Inhibitors of PLD are classified into PLD1, PLD2 and dual PLD 
inhibitors. 
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PLD1 and PLD2 inhibitors specifically inhibit PLD1 and PLD2 respectively, 
while the dual inhibitor is less specific, but efficiently inhibits both PLD1 and PLD2 
isoforms. 
PLD is known to be implicated in pathological conditions, and hence it is 
necessary to inhibit the pathological effects of PLD such as in inflammation, cancer 
metastasis and invasion. Early uses of PLD inhibitors included primary alcohols such as 
ethanol and butanol. But it was later realized that these alcohols did not inhibit PLD 
activity but deviated the product from phosphatidic acid to phosphatidyl-ethanol or –
butanol, which is being used in in vitro measurement of lipase activity with the help of 
radiolabelled [3H]- butanol. Also the use of primary alcohols led to many off target 
effects wherein ethanol was found to inhibit neutrophil functions of PLD (Sato, Hongu et 
al. 2013).  
Aluminum fluoride is known to activate PLD in intact cells, but was found later 
that it inhibited PLD in cell extracts/lysates and permeabilized cells. This difference was 
attributed to the fact that in extracts, Aluminum fluoride acts on inhibition-causing target 
in intact cells, which might be the enzyme itself (Li and Fleming 1999). During the 
purification of PLD from granulocytes, PLD activity was found to be inhibited by a 
commonly-used protease inhibitor cocktail. The cocktail consisted of six inhibitors, the 
serine protease inhibitor 4-(2- aminoethyl)-benezensulfonyl fluoride (AEBSF) was the 
sole inhibitor of PLD (Andrews, Bond et al. 2000). This correlation of a serine protease 
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inhibitor in inhibiting a lipase like PLD attributes to the fact that PLD has histidine and 
aspartic acid in its catalytic active site similar to a serine protease. Due to some 
drawbacks, such as high inhibitor concentration unsuitable for in vivo applications, more 
specific and efficient small molecule inhibitors of PLD have been developed recently.  
The base for most of the current small molecule inhibitors of PLD2 are 
“halopemides” (Monovich, Mugrage et al. 2007). Halopemides were found to inhibit 
dopamine receptors and evaluated to be neuroleptic agents (Seeman, Grigoriadis et al. 
1986). FIPI (5- fluoro-2 indolyl des-chlorohalopemide is a derivatives of halopemide and 
tested for its ability to inhibit PLD. It was observed that the 2-indolyl added to the 
halopemide made it a potent inhibitor of PLD (IC50 ~ 0.020µM). Of the two compounds 
that had 2-indolyl, the one with a p-fluorophenyl in the side chain was even more potent 
during pharmaco-kinetics studies with a half-life greater than 5 h. And the potency versus 
PLD2 was improved to 75-fold that was unmatched in a set of fused bicyclic 
heterochromatic compounds (Monovich, Mugrage et al. 2007). Another study with PLD1 
shows that FIPI is a potent PLD1 inhibitor. PLD1 has lower basal activity and hence 
stimulating it with PMA followed by inhibition with FIPI gave an IC50~1nM (Su, Yeku et 
al. 2009). 
Since PLD1 has been well studied by many other scientists in the field such as 
Michael A. Frohman and Ryu, showing their importance in cancer and inflammation, we 
have been interested in PLD2. As in a recent study we have shown the importance of 
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PLD2 in cancer metastasis and invasion, it is necessary to inhibit PLD2 in such 
pathological conditions. Hence another inhibitor of interest is PLD2 specific N-[2-[1-(3-
Fluorophenyl)-4-oxo-1,3,8-triazaspiro[4.5]dec-8-yl]ethyl]-2-naphthalenecarboxamide 
(NFOT). It has been shown in a recent study that NFOT is an isoform selective inhibitor 
of PLD specific to PLD2 (Lavieri, Scott et al. 2010).  
The study also indicated that developing PLD2 specific inhibitors is difficult and 
that NFOT is 75 folds selective to PLD2 with an IC50 of 20 nM. Another PLD2 specific 
inhibitors was developed an year earlier to NFOT called N-[2-(4-oxo-1-phenyl-1,3,8-
triazaspiro[4,5]dec-8-yl)ethyl]-2-naphthalenecarboxamide (NOPT) (Lewis, Scott et al. 
2009). This was more specific to PLD2 but has an IC50 greater than NFOT and is less 
potent compared to NFOT. NFOT is also a [4.5]dec-8-yl]ethyl]-2-naphthalenecar
boxamide derivative but has a fluorophenyl instead of oxo-phenyl making it more potent 
compared to NOPT. 
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MATERIALS AND METHODS 
Materials 
 The COS-7, African black monkey kidney fibroblasts were purchased from ATCC. 
COS-7 culture medium Dulbecco’s modified eagle medium (DMEM), Fetal Bovine 
Serum and TransfectaGRO were obtained from Corning Cellgro® (Manassas, VA). 
Lipofectamine, Plus and EGF were purchased from Invitrogen (Carslbad, CA). 3[H]- 
butanol was obtained from Perkin Elmer (Waltham, MA). All the phospholipids required 
for lipase enzyme activity assay including PC8 and PIP2 were purchased from Avanti 
Polar Lipids. Matrigel inserts were purchased from BD (Franklin Lakes, NJ). 
Hematoxylin stain was obtained from Ricca (Arlington, TX). Phospholipase D (PLD) 
inhibitors were obtained from Cayman Chemicals, Avanti polar lipids and Tocris 
biosciences. 
Methods 
Cell culturing and Plasmid transfections 
COS-7 cells were cultured and sub-cultured in DMEM with 10% FBS, 50 U/ml 
Penicillin, 50 U/ml Streptamycin and 50µg/ml Gentamycin at 37⁰C temperature and 5% 
carbon-dioxide in a CO2 incubator. Cells were split at 80% confluence. The cells were 
transfected at 60% confluence per well with plasmids ranging from 1-6 µg of DNA, using 
6µl Lipofectamine and 6 µl Plus diluted in 600 µl TransfectaGRO. Sterile glass culture 
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tubes housed each liposome (DNA+Lipid complex) prior to transferring the solution into 
6-well plates of cells containing 1 ml of TransfectaGRO. The transfection mix was 
allowed for 3 hours and then the media is aspirated and changed to fresh complete 
DMEM. Transfection is allowed to go for 48 hours. 
Phospholipase activity assay 
Lipase activity measurement began with addition of the following reagents to 50 µl of 
lysates: 3.5 mM PC8 phospholipid, 0.9 mM PIP2 phospholipid and 0.5 µCi of n-[3H] 
butanol (Perkin-Elmer, MA) making the final reaction volume 120 µl. Samples were 
incubated for 20 minutes at 30⁰C with continuous shaking. The reactions were then 
stopped by adding 200 µl ice-cold stopping solution, 75 µl of Chloroform and 25 µl of 
water. After stopping the reactions, the eppendorfs were capped tightly, vortexed twice 
and spun at 14000g for 1minute. Three layers were obtained after spinning. The top layer 
was discarded and the bottom-most layer was pipetted carefully and transferred into a 
fresh vial. This was dried under N2 gas and resuspended in chloroform: methanol (9:1). 
This was spotted on Thin-layer chromatography plates along with phospholipid controls 
p-ethanol and p-butanol. The plate was kept in a chamber containing solvent (Ethyl 
acetate: Iso-octane: acetic acid: water) and allowed to separate by thin-layer 
chromatography. Then the samples were read in scintillation counter for lipase activity by 
measuring the radioactivity of the samples. 
Enzyme Competition Assay 
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1x 106 Cells were cultured and transfected with 2µg PLD1 or PLD2, 48 h post-
transfection, cells were starved for 2 h, stimulated with EGF (3nM) and made lysates. 
These lysates were treated with 100 nM PLD1 inhibitor (NBOD), PLD2 (NFOT) 
inhibitor or dual inhibitor (FIPI) for 25 min. After treatment with the inhibitor, the lysates 
were subject to lipase activity assay as mentioned above, but with increasing 
concentrations of PC8, which is the substrate of PLD. The phospholipase activity of the 
enzyme was measured by measuring the radioactivity in a scintillation counter. 
Western blotting 
The cells after stimulation were made into lysates. These lysates were made in desired 
volume of Special lysis buffer (50mM HEPES, pH 7.2, 100 µM NA3VO4, Triton X-100 
and 5 mg/ml each of protease inhibitors (aprotonin and leupeptin)) and sonicated. BIO-
RAD protein estimation assay was utilized to determine the protein concentration and to 
normalize for protein per reaction.  
Desired concentration of protein was loaded into the wells of SDS-PAGE gels along with 
a molecular weight marker. These gels were then transferred for 1 h onto PVDF 
membrane, blocked for 45 min at room temperature with 1% BSA with TBS, 0.2% 
Tween 20 and probed with primary antibody overnight. The blots were then washed with 
TBS-T and probed with secondary antibody conjugated to horse radish peroxidase (HRP) 
and detected on x-ray films with the help of ECL western blotting detection reagents 
from GE Health Care (Fairfield, CT). The Kodak Gel Logic software used to perform 
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densitometry on western blots which consists of quantifying the bead of the protein of 
interest versus the band of the actin loading control.  
Cell migration  
Adherent cells were detached using 25% Trypsin/EDTA or a non-enzymatic cell 
dissociation buffer for COS-7 or RAW cells, respectively. A hemocytometer was used to 
count cells, and trypan blue exclusion was used to determine cell viability. 24-well plates 
and Transwell inserts were pre-wetted with DMEM containing 0.5% BSA. Cell 
concentration was adjusted to 5 x 104 cells per 400µl of DMEM containing 0.5% BSA 
per insert. 600µl of DMEM containing 5% BSA was added to the bottom of the well 
prior to placing the cells and insert in the well. Either 100 ng/µl EGF for COS7 cells was 
used as chemoattractants. The murine macrophage cells lines were allowed to chemotax 
for 3.5 hours and COS-7 cells chemotaxed for 1 hour at 37◦C, 5% CO2. Afterward, 
inserts were removed and cells that had migrated to the bottom were fixed with 4% 
paraformaldehyde per each well. Cells that migrated to the bottom were then allowed to 
settle and adhere before being counted. Cells were then counted using an inverted 
microscope at 20x. The average numbers of 6 counts per well were taken and data is 
quantified. 
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RESULTS 
Aim 1:  To determine the kinetics of the PLD inhibitors: Is it Reversible or 
irreversible? 
Rationale 
All PLD inhibitors considered in the present study are compounds that inhibit the lipase 
activity of PLD. Earlier many non-specific inhibitors of PLD such as primary alcohols 
and AEBSF were found. But due to their non-specific interactions or very high 
concentration requirements they could not be used. Recently, many specific small 
molecule inhibitors of PLD have been developed. However it is not clearly known 
whether these inhibitors are competitive or non-competitive or mixed inhibitors.  
If the inhibitor can be classified as competitive or non-competitive, it would be 
suggestive of the site of action, as competitive predominantly binds in the catalytic site 
and also in some allosteric site, but via non-covalent interactions that can be knocked out 
by higher substrate concentrations. While in case of non-competitive, substrate cannot be 
knocked out by increasing the substrate concentration.  
In case of a mixed inhibition, we might say that in some regions inhibitor binding 
are by weak interactive forces that allow recovery of enzyme activity to a certain extent 
and saturate. 
Purification of Phospholipase D2 protein 
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Experimental approach 
Recombinant PLD2 was made by infecting Sf21 insect cells with pBacC1-mycPLD2a-
WT passage 2 virus (Gomez-Cambronero and Henkels 2012). The cells were infected 
with 10 times of the virus to the number of cells in the culture. This infection was 
allowed to go for 5 days. 5 days post-infection, cells were harvested and made into 
lysates. The lysate was then purified by batch purification using Cobalt conjugated 
TALON His-Tag purification resin. The PLD2 virus used here has 6-HN repeats and is 
pulled down by the TALON resin. Finally the protein is eluted by a series of elution 
buffer washes, wherein the elution buffer has imidazole to release the Histidine-Cobalt 
bond.  
Results 
All the elutions, washes, flow through and crude samples were then run on a gel to test 
for purity and specificity of PLD2 protein. Coomassie brilliant blue staining (Fig. 6) was 
performed to look at the purity of the recombinant PLD2 protein. Also immunoblotting 
(Fig. 7) was done for myc-tag on PLD2. After having looked at the purified protein being 
PLD2, the lipase activities (Fig. 8) of the various samples were measured and we found 
that first 3 eluates have good lipase activity. 
Optimization of PLD assay time  
Experimental approach 
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The enzyme competition assays were performed with recombinant PLD2 and all other 
experiments were done with either whole cells or cell lysates. It is important to optimize 
the duration of lipase assay in order to obtain the highest activity under uninhibited 
conditions, while getting the largest inhibition when treated with inhibitor. The 
recombinant protein and the lysates were treated with inhibitors first and then subject to 
lipase activity assay for different time points of 0, 5, 10, 15 and 20 mins.  
Results 
It was found that 15 mins was an optimal time point to stop the PLD assay as the lipase 
activity (Fig. 9 and 10) was the highest, while the inhibition was largest when treated 
with inhibitors. 
IC50 of specific PLD inhibitors on lipase activity 
It is important to know the IC50 of inhibitors in order to verify the potency and specificity 
of the inhibitors to their targets. Moreover, the IC50 varies from cell to cell. The IC50 of all 
the PLD inhibitors was determined (Fig. 11-17) and it was observed that only the PLD2 
specific inhibitors and the dual PLD inhibitor worked efficiently and hence studies were 
performed with dual PLD inhibitor, FIPI, and PLD2 specific NFOT.  
 The IC50 of the specific PLD inhibitors NFOT and FIPI in COS7 cells was found to be 
~11 nM and ~6 nM respectively. (Fig. 13 and 15) 
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All the PLD assay experiments were done by starving and stimulating the cells 
prior to inhibitor treatment. Increasing concentrations of PLD inhibitors ranging from 
0nM to 1000 nM were used. 
 
Enzyme-kinetics of PLD2 with inhibitors FIPI or NFOT and substrate PC 
Experimental approach 
All the enzyme competition assays were performed with recombinant PLD2. Before 
treating PLD2 with inhibitors, the IC50 of PLD inhibitors was determined and it was 
observed that only the PLD2 specific inhibitors and the dual PLD inhibitor worked 
efficiently and hence studies were performed with dual PLD inhibitor, FIPI, and PLD2 
specific NFOT and/or NOPT.  
To test if PLD2 inhibition was reversible or irreversible increasing concentrations of the 
purified PLD2 enzyme was treated with a fixed concentration of the substrate PC (3.5 
mM) and inhibitor 300 nM FIPI or NFOT and enzyme competition assay was performed. 
Another assay to study the mechanism was enzyme kinetics assay or the lipase assay of 
recombinant purified PLD2 protein with increasing substrate concentrations and 
treatment with vehicle or 300 nM inhibitor FIPI or NFOT. Recombinant PLD2 was 
treated with inhibitor first, after which they were subject to treatment with increasing 
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concentrations of the substrate PC8 ranging from 0mM to 55mM and a fixed 
concentration of the effector PIP2 (0. 09mM).  
Results 
It was found that with FIPI the inhibition is irreversible as the PLD activity did not 
increase with increasing concentrations of the enzyme even after a E-I threshold was 
surpassed, whereas with NFOT,  the inhibition was reversible as the PLD activity (Fig. 
18) was regained after increasing the enzyme concentration.  
For the second assay it was observed that in control group (Vehicle (DMSO) treated), 
PLD activity increased with increasing concentrations of the substrate. However, in 300 
nM FIPI and NFOT treated cells, PLD activity (Fig. 19 and 20) dropped initially, but 
increased at higher concentrations of the substrate PC approaching the control levels. 
Michaelis-menton kinetics and line-weaver burk plot were used to plot the data 
suggesting different Km and Vmax when treated with FIPI or NFOT. 
Enzyme-kinetics of PLD2 with inhibitors FIPI or NFOT and effector molecule PIP2 
Experimental approach 
Recombinant PLD2 was treated with inhibitor first, after which they were subject to 
treatment with increasing concentrations of the effector PIP2 ranging from 0nM to 3µM 
and a fixed concentration of the substrate PC8 (3.5mM) at the beginning of lipase assay. 
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Lipase assay of recombinant purified PLD2 protein with increasing concentrations of its 
positive effector PIP2, in the presence of vehicle or 300 nM FIPI or 300nM NFOT was 
also performed to observe changes in Km and Vmax. 
Results 
It was found that PIP2 has two binding sites. It suggests that PIP2 exerts both a positive 
effect and a negative effect on PLD2. At low (<1 mM) concentration of PIP2, PLD is 
activated, but as the substrate increase, the activity returns to basal level. It also suggests 
that the specific PLD2 inhibitor NFOT binds to the site occupied by PIP2, so NFOT 
blocks PIP2 binding and negates its positive effect on PLD2 activity. While on the other 
hand, FIPI is found to be irreversibly inhibiting PLD2 by covalent modifications not 
allowing PIP2 to bind to PLD2 (Fig. 21).  
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Aim2:  To determine the site of action of PLD inhibitors. 
Rationale 
PLD has many physiological as well as pathological roles. Some of the physiological 
roles of PLD are chemotaxis, cell migration, DNA synthesis and phagocytosis. 
Unregulated activity of PLD2 results in pathological role of PLD in chronic 
inflammation, cancer metastasis. Therefore there is a need to find a specific small 
molecule inhibitor for PLD. Elucidating the mechanism of action of existing small 
molecule inhibitors of PLD is one approach to design more potent inhibitors. This 
specific aim is designed to screen various PLD mutants whether they exhibit resistance 
for PLD inhibitors. The site of action of these small molecule inhibitors needs to be 
known to develop more potent and specific PLD inhibitors. It is also know that these 
inhibitors are hydrophobic in nature and hence mutating highly hydrophobic residues to 
less hydrophobic suggesting if that mutant is resistant to be inhibition by the FIPI and/or 
NFOT, then that is the possible site of action of inhibitor.  
Screening for mutants with intact lipase activity 
Experimental approach 
Several mutants of PLD (Fig. 22 and 23) in the PX, PH and around HKD regions were 
designed in order to screen the resistance against inhibitors. Some of the mutants in PX 
region are: F107Y, L110A, L126A, F129Y, H158Q, Y165F, L166A, R172C, L173A, 
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R172C/L173A, Y169F, Y179F, Y169F/Y179F. Mutations in the PX regions were made 
in order to make hydrophobic residues such as leucine, arginine and tyrosine to either less 
hydrophobic or hydrophilic alanine. 
Mutants designed in PH and around the HKD region are: R210A/R212A, 
F244N/L245A/L246A, P263A, K292A, Y296F, Y415F, S648A, D649A, R651A, S757A 
and S771A. Even the PH mutants were designed by changing the hydrophobicity of the 
residues from highly hydrophobic to less hydrophobic or hydrophilic to hydrophilic 
alanine. HKD mutants were designed by docking the substrate and the inhibitor on PLD2 
by the use of bioinformatics. 
All the above listed mutants were screened for intact lipase activity when 
compared to PLD2-WT. Only those mutants with lipase activity more than 60% when 
compared to WT were chosen for further experiments with inhibitors. It is important to 
know that the mutation is intact as making mutations might affect the secondary and 
tertiary structure of the protein causing faulty enzymatic activity or loss in enzyme 
activity. 
Results 
Among the 12 PX mutants F107Y, L126A, F129Y, H158Q, Y165F, R172C, L173A, 
R172C/L173A, Y169F, Y179F, Y169F/Y179F were found to have intact lipase activity 
(Fig. 24). 
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Among the PH mutants (Fig. 25) only F244N/L245A/L246A, P263A and K292A 
had intact lipase activity. Of the five HKD mutants (Fig. 26) S648A, D649A, R651A, 
S757A and S771A, all except S771A (found to be lipase inactive) had intact PLD 
activity. Since PLD2 is our molecule of interest, the inhibitors used in this study are 
NFOT (PLD2 specific) and FIPI (dual PLD). 
 
Effect of DMSO on lipase activity 
Experimental approach 
Most of the PLD inhibitors are hydrophobic and soluble only in organic solvents like 
DMSO. DMSO by itself has a role in cell differentiation: 1.25% DMSO is used of cell 
differentiation and might alter the enzyme activities in a cell. Therefore it is essential to 
determine the effect of DMSO on lipase activity. In order to normalize the percentage of 
DMSO that can be subjected to the cells and cell lysates, the cells were treated with 
increasing concentrations of DMSO ranging from 0 % to 1 %. 
Results 
Figure 27 suggests that in cells treated with DMSO up to 1%, the lipase activity is not 
affected. We therefore were safe at using 0.16% final concentration of DMSO per 
reaction. 
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Effect of inhibitors of PLD activity of PLD2 mutants 
Experimental approach 
All the mutants of PLD were treated with 300 nM FIPI and 300 nM NFOT, since at least 
3-10 times the IC50 is recommended for use. Cells were transfected with the screened (for 
intact lipase activity) mutant plasmids and 48 h post-transfection, lysates were made in 
special lysis buffer with protease inhibitors. These lysates were either treated with 
inhibitors or with vehicle (DMSO) for 25 min and these samples were then subjected to 
PLD activity assay (Fig. 28-30). 
The PX, PH and HKD mutants that were resistant or partially resistant to 
inhibition by NFOT and/or FIPI were subject to increasing doses of the inhibitors FIPI 
and NFOT (Fig. 31-34).  
Results 
It was observed that the mutants PLD2-F244N/L245A/L246A and PLD2-S648A are 
resistant to inhibition over a range of inhibitor concentrations of NFOT (Fig. 35).  
We speculate that the residues F244/L245/L246 in the PH region and S648 in the 
HKD motif has to be intact for the action of NFOT. Using the coordinates of 
F244/L245/L246 and S648 specifically, more potent and sensitive inhibitors can be 
designed.  
	   	   37	  
	   	   	   	  
 
Functional relevance of PLD2 mutations and PLD2 inhibition 
Experimental approach 
In order to see if the mutations of PLD2 or PLD2 inhibition had any effect on the 
functions of PLD such as chemotaxis, we selected the most promising mutants and 
subjected them to chemotaxis (Fig. 36). The cells that were over-expressed with mock or 
PLD2-WT or one of the 7 mutants of PLD2 such as F129Y, H158Q, Y165F, R172C, 
L173A, R210A/R212A, F244N/L245A/L246A and S648A were treated with vehicle or 
300 nM NFOT or FIPI and subject to chemotaxis (COS7s). 
Results 
It was found that the chemotactic ability of these mutants was intact but all the mutants 
except S648A were inhibited when treated with the inhibitors FIPI and/or NFOT (Fig. 
37). These findings suggest that the mutants have functional relevance to PLD2-WT.  
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Aim 3: To determine the role of interacting proteins on the action of PLD inhibitors. 
Rationale 
As mentioned earlier, PLD2 has several protein-binding partners in the cell at any given 
time (Knapek, Frondorf et al. 2010). Upon inhibitor treatment in vivo, protein partners of 
PLD might interfere with inhibitor action. Therefore in this aim, we sought to determine 
the inhibitors action in the presence or absence of binding partners. In the present study 
we choose two binding partners of PLD2, Grb2 and Ras. These proteins were chosen 
because of their important role in both physiological processes like cell migration as well 
as in cancer metastasis.  
In a recent study it was shown that in the presence of Grb2 PLD2 activity 
increases in vivo stimulating the Erk/MEK pathway of cell proliferation (Henkels, Short 
et al. 2009). Another study showed that Grb2 is in a heterotrimer of PLD2-Grb2-WASp 
stimulates leukocytes phagocytosis wherein PLD2 interacts with Grb2 and grb2 interacts 
with WASp through its SH3 domains resulting the activation of Arp2/3 which is involved 
in actin nucleation and forms filopodia and a phagocytic cup (Kantonen, Hatton et al. 
2011).  
If these binding partners indeed show positive or negative effect on the action of 
inhibitors, other binding partners will be studied further. Also it will provide important 
information regarding inhibitor doses employed in situations of inflammation and cancer. 
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Under such pathological conditions the protein partner’s effect on inhibitor action might 
have to be taken into consideration while employing inhibitor doses.  
 
Effect of binding partners of PLD2 upon treatment with PLD inhibitors 
Experimental approach 
COS7s were silenced with 200 nM siRas and overexpressed with PLD2-WT for 48-72 h 
with a boost of 100 nM siRas a day after overexpression of PLD2-WT. Cells were 
harvested and lysates were prepared, which were subjected to increasing concentrations 
of the inhibitors FIPI and NFOT for each experimental group (PLD2-WT only or siRas + 
PLD2-WT).  
Results 
In a lipase assay following treatment with increasing doses of inhibitor, it was found that 
silencing Ras (Fig. 38 and 40) showed a positive effect on PLD2 lipase activity that 
increased marginally. But treatment with inhibitor did not protect this activity showing 
decreased PLD2 activity with increasing inhibitor concentrations. 
Role of interacting proteins Grb2 and Ras on PLD activity  
Experimental approach 
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To confirm the effect of Grb2 in PLD2 inhibition, COS7s were then overexpressed with 
PLD2 only or both PLD2 and Grb2. Normally an increase of 4-5 folds in activity is 
observed in lysates from cells that have been transfected 1-2 days with pcDNA3.1-
mycPLD2a-WT.  After 48 h of transfection, cells were harvested and lysates were 
prepared. These lysates were subjected to PLD activity assay and Western blot analysis.  
Results 
Overexpression of Grb2 showed an increase in PLD activity compared to mock 
transfected cells. Upon treatment with 300nM of inhibitors FIPI or NFOT, lipase activity 
of mock cells decreased rapidly, while the Grb2 overexpressed cells (Fig. 41) when 
treated with 300nM NFOT showed resistance, but when treated with 300nM FIPI PLD2 
activity was inhibited (Fig. 39).  Summarily, these inhibition experiments with binding 
partners conclude that while employing inhibitors in vivo, several factors including 
binding partners of the target protein has to be taken into consideration. A schematic 
summarizing this shows the interaction of Grb2 and PLD2 suggesting PLD2 activity is 
positively regulated by Grb2, and this interaction protects PLD2 from inhibition by 
NFOT (Fig. 42). 
Overexpression of Grb2 was confirmed by western blot analysis. The assay showed an 
increase in PLD activity upon co-transfection with Grb2 in COS7s.  
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DISCUSSION 
Our findings suggest that Phenylalanine244 through leucine 246 and serine 648 within 
the allosteric site and the catalytic site are essential for the action of inhibitors on PLD2 
and that mutating these key amino acid(s) results in partial resistance of the enzyme 
towards the inhibitor. In addition, the inhibitor’s action on PLD2 is effected by the 
presence or absence of protein interacting partners of PLD2 such as Grb2.  
PLD binds to Grb2 and recruits Sos, while PLD-derived PA directly binds to Sos, 
both ultimately promote GTP loading of Ras and stimulates the MEK/ERK pathways 
(Zhao, Du et al. 2007) that are key regulators of cell migration and DNA synthesis. In 
addition PLD2 itself acts as GEF for Ras (Henkels, Mahankali et al. 2013). Activation of 
Ras-guanine nucleotide exchange factor, Sos by interaction of SH3 of Grb2 with C-
terminal Proline-rich regions in Ras and Sos is a well characterized mechanism that 
results in the activation of MAPK cascade and cell proliferation (Chardin, Camonis et al. 
1993; Egan, Giddings et al. 1993). Our finding suggests that Ras negatively regulates 
PLD2, wherein in the absence of Ras, PLD2 activity is increased significantly. In 
addition, inhibitor experiments with Ras and PLD2 suggested that the presence of Ras did 
not affect inhibition of PLD2 by FIPI or NFOT.  
As we know that Grb2 is central to many intracellular signaling pathways and that 
Grb2 interacts with phosphotyrosine residues on PLD2 via SH2 domains triggering 
chemotaxis and cell migration, it is essential to see the effect of Grb2 in PLD2 inhibition 
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by PLD2 inhibitors. We found that Grb2 positively regulates PLD2 at lower 
concentrations of inhibitors by protecting it from inhibition, but at higher concentrations 
the activity is inhibited. This suggests that Grb2 interaction with PLD2 allows the binding 
of inhibitors thereby enhances efficiency of the inhibitors.  
This is the first study where we attempted to elucidate the kinetics of PLD2 
inhibitors. Lineweaver-burk (LB) plot (Fig. 17) shows that FIPI and NFOT inhibit PLD 
by increasing Km and decreasing Vmax values, which therefore is by mixed inhibition. 
Mixed inhibition suggests a wide repertoire of binding sites on PLD2 including both 
catalytic and regulatory regions. However, mixed inhibition of PLD2 by FIPI and NFOT 
does not suggest anything specific about their binding site on PLD2.  To explore the site 
of action, we designed wide range of mutants within the PX, PH and HKD regions of 
PLD2.  
PIP2 exerts both a positive effect and a negative effect on PLD2. At low (<1 mM) 
concentration of PIP2, PLD is activated, but as the substrate increase, the activity returns 
to basal level. If PIP is added to cell lystes of overexpresing PLD2 a strong negative can 
be documented. We also report that the specific PLD2 inhibitor, N-[2-[1-(3-
Fluorophenyl)-4-oxo-1,3,-8-triazaspiro[4.5]dec-8-yl]ethyl]-2-naphthalenecarboxamide 
(NFOT) binds to PLD2 at two different sites, one being at the catalytic site (HKD motifs) 
at S648, and another to an allosteric site that is the natural site occupied by PIP2, so 
NFOT blocks PIP2 binding and negates its positive effect on PLD2 activity. 
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Our data suggests that the mutants F244N/L245A/L246A and S648A are resistant 
to inhibition by the inhibitor NFOT. Thus the binding site of the inhibitor NFOT are 
found to be F244/L245/L246 and S648 suggesting it binds to regulatory regions of PLD2 
possibly affecting the binding of the effector PIP2 binding to PLD2 as well as the 
catalytic site.  
Thus we developed a working model with this study showing the effect of 
inhibitors, type of inhibition on PLD2 and the role of interacting partner Grb2 in 
inhibition of PLD2 by FIPI or NFOT (Fig. 43). The model shows that NFOT binds to an 
allosteric site with high affinity and with comparatively low affinity to the catalytic site 
on PLD2. Upon PLD2 interactions with Grb2 via phosphorylated tyrosine residues, 
PLD2 activity is resistant to inhibition by NFOT, while FIPI results in an irreversible 
inhibition, presumably by covalently modifying the catalytic site. Ras has a negative 
effect on PLD2 activity. 
From our findings on the action of the two PLD2 inhibitors, FIPI and NFOT, one 
could say the two have different modes of action. FIPI could possibly act by modifying 
the enzyme totally not allowing the protein partners such as Grb2 to interact with PLD2, 
whereas NFOT interacts at both the catalytic and allosteric sites suggesting two sites of 
action. The two sites for action of NFOT could possibly be accounted for by its structure 
wherein the fluoride possibly interacts at the catalytic site and the two benzyl rings 
interact at the allosteric site. Another finding from our study that would correlate with 
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FIPI action is the inhibition of PLD2 significantly higher than PLD1 by NBOD that also 
has fluoride, is available as a selective PLD1 inhibitor in the market. 
Determining the site of action, mode and microenvironment of inhibitor action 
would help in developing more potent inhibitors of PLD2 which can be used in vivo in 
studying their effects on pathological conditions implicated by PLD2. 
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Halopemide 
 
N-[2-[4-(5-chloro-2,3-dihydro-2-oxo-1H-
benzimidazol-1-yl)-1-piperidinyl]-ethyl]-4-
fluoro-benzamide 
(Monovich, Mugrage et al. 2007) 
FIPI 
 
5-Fluoro-2-Indolyl des-Chlorohalopemide 
(Su, Yeku et al. 2009) 
NFOT  
 
N-[2-[1-(3-Fluorophenyl)-4-oxo-1,3,-8-
triazaspiro[4.5]dec-8-yl]ethyl]-2-
naphthalenecar-boxamide 
(Lavieri, Scott et al. 2010) 
NOPT 
 
N-[2-(4-oxo-1-phenyl-1,3,8-
triazaspiro[4,5]dec-8-yl)ethyl]-2-
naphthalenecarboxamide 
(Lewis, Scott et al. 2009) 
NBOD 
 
N-[2-[4-(5-chloro-2,3-dihydro-2-oxo-1H-
benzimidazol-1-yl)-1-piperidinyl]-1-
methylethyl]-2-naphthalenecarboxamide 
(Lavieri, Scott et al. 2009)	  
RBPC 
 
(1R,2R)-N-([S]-1-{4-[5-bromo-2-oxo-2,3-
dihydro-1H-benzo(d)imidazol-1-
yl]piperidin-1-yl} propan-2-yl)-2- 
phenylcyclopropanecarboxamide 
(Lewis, Scott et al. 2009) 
 
Table 1. PLD inhibitors. The table shows a list of PLD inhibitors and their stucture    
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Fig 6. Coomassie brilliant blue gel staining of PLD2 protein purification. This gel 
shows the purity of recombinant PLD2-WT made by batch purification.   
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Fig 7. Western blot analysis of myc-PLD2. This image shows the purified PLD2 
protein has myc tag.    
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Fig 8. Lipase activity of PLD2 purification samples. This figure shows the intact lipase 
activity of the eluates of PLD2 obtained during batch purification.  
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Fig 9. Lipase activity of recombinant PLD2. This figure shows the determination of 
optimal time of lipase activity and inhibition of recombinant PLD2. 
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Fig 10. Lipase activity of overexpressed PLD2. This figure shows the determination of 
optimal time of lipase activity and inhibition of PLD2 overexpressed in cells.  
  
Duration of lipase assay (min)
0 5 10 15 20
P
ho
sp
ho
lip
as
e 
ac
tiv
itt
y 
(%
 M
ax
)
0
20
40
60
80
100
Control
300 nM NFOT
300 nM FIPI
Recombinant PLD2
0 5 10 15 20
0
20
40
60
80
100
Duration of lipase assay (min)
Overexpressed PLD2
P
ho
sp
ho
lip
as
e 
ac
tiv
itt
y 
(%
 M
ax
)
Cr
ud
e
Flo
w 
Th
ru
Wa
sh
 1
Wa
sh
 2
Wa
sh
 3
Elu
ate
 1
Elu
ate
 2
Elu
ate
 3
Elu
ate
 4
Elu
ate
 5
Elu
ate
 6
110KDa
WB α-myc
Purification Rec. PLD2 from pBacC1-mycPLD2a-WT
Eluate 1 = 340 ng/ml
Eluate 3 = 60 ng/ml
Eluate 2 = 180 ng/ml
Eluate 4 = 10 ng/ml
Figure 2
Control
300 nM NFOT
300 nM FIPI
[PC8] (μM)
E
[D
P
M
/m
g 
of
 p
ro
te
in
]
0 10 20 30 40
0
50
100
150
200
250
300 300 nM FIPI
300 nM NFOT
No inhibitor Substrate
50 75 100 125 150
P
ho
sp
hn
ol
ip
as
e 
ac
tiv
ity
 (%
 c
on
tro
l, 
no
in
hi
bi
to
r)
0
20
40
60
80
100
120
140
160
0
D
300 nM FIPI
300 nM NFOT
No inhibitor
180
200
220
100 ng/μl ~ 830 nM
Enzyme
[Recombinant PLD2] (ng/μl)
A
B C
[1/ PC8] (mM-1)
1/
[D
P
M
/m
in
/u
g 
of
 p
ro
te
in
]
FIPI
NFOT
Control
-1.0 -0.5 0.0 0.5 1.0 1.5
0.002
0.004
0.006
0.008
0.010
0.012
0.014
0.016
0.018
0.020
0.022
0.024 No inhibitor
300 nM FIPI
300 nM NFOT
F
-1.5
Figure 2
	  
	   	   51	  
	   	   	   	  
 
Fig 11. RBPC IC50. Shows the dose-response curve of PLD1 specific inhibitor RBPC in 
COS7s, wherein PLD2 is inhibited instead of PLD1 
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Fig 12.  NBOD IC50. Shows the dose response curve of a PLD2 specific inhibitor that 
inhibits PLD1 and PLD2 with IC50 of 9 nM and 20 nM respectively in COS7s 
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Fig 13.  NFOT IC50. Shows the dose response curve of a PLD2 specific inhibitor that 
inhibits PLD2 alone with an IC50 of 10 nM in COS7s  
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Fig 14.  NOPT IC50. Shows the dose response curve of a PLD2 specific inhibitor that 
inhibits PLD2 with an IC50 of 45 nM in COS7s  
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Fig 15.  FIPI IC50. Shows the dose response curve of a dual PLD inhibitor that inhibits 
both PLD1 and PLD2 with an IC50 of 10 nM and 8 nM respectively in COS7s  
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Fig 16.  NFOT IC50 in whole cells. Shows the dose response curve of a PLD2 specific 
inhibitor that inhibits only PLD2 with an IC50 of 10 nM respectively in COS7s  
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Fig 17.  FIPI IC50 in whole cells. Shows the dose response curve of a dual PLD inhibitor 
that inhibits both PLD1 and PLD2 with an IC50 of 7 nM and 8 nM respectively in COS7s 
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Fig 18. Enzyme Kinetics: Reversible or irreversible. Shows the lipase activity assay of 
FIPI and NFOT respective to the control, suggesting FIPI is irreversible and NFOT is 
reversible. 
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Fig 19. Enzyme competition assay: Michaelis-menton kinetics. Shows the michaelis-
menton kinetics plot of FIPI and NFOT respective to the control, suggesting FIPI and 
NFOT are non-competitive or mixed PLD inhibitors 
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Fig 20. Enzyme competition assay: Lineweaver-burke plot. Shows the lineweaver-
burke plot of FIPI and NFOT respective to the control, suggesting FIPI and NFOT are 
non-competitive or mixed PLD inhibitors as the inhibitor Km and Vmax are not equal to 
control suggesting both the catalytic binding and rate of action of the enzyme are affected 
by the inhibitors. 
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Fig 21. Allosteric regulator (PIP2) of PLD: Enzyme kinetics. Shows a plot of PLD 
enzyme activity vs increasing dose of PIP2 in the presence or absence of FIPI or NFOT, 
suggesting FIPI inhibits PLD2 at a different site than the allosteric regulator PIP2 
interaction site, while NFOT inhibition is partially rescued by increasing concentrations 
of PIP2 suggesting binding site of PIP2 could be possibly the site of interaction of NFOT 
as well. 
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Fig 22. Mutations in PLD2. This is a representative of the various mutations in PLD2 in 
the regulatory PX and PH domains, as well as in and around the catalytic HKD motifs. 
The mutations in the regulatory domains are made based on hydrophobicity, making 
more hydrophobic residues to less hydrophobic or hyrodphilic and the mutations in 
catalytic domains are made by docking the substrate and inhibitors on PLD2. Also the 
residues in and around HKD were mutated into less hydrophobic alanine. 
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Fig 23. Optimization of mutants for transfection. All the selected mutations from PX, 
all the mutations made in PH and HKD were optimized for transfection shown in a 
western blot representative of the protein expression post-transfection.   
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Fig 24. Screening of intact lipase mutants in the PX region. All the mutations made in 
the PX domain were screened for intact lipase activity as making mutations might affect 
the protein structure and function. Mutants that had 60% or more activity compared to 
WT were considered intact. 
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Fig 25. Screening of intact lipase mutants in the PH region. All the mutations made in 
the PH domain were screened for intact lipase activity as making mutations might affect 
the protein structure and function. Mutants that had 60% or more activity compared to 
WT were considered intact.  
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Fig 26. Screening of intact lipase mutants in the HKD region. All the mutations made 
in and around the HKD motifs were screened for intact lipase activity as making 
mutations might affect the protein structure and function. Mutants that had 60% or more 
activity compared to WT were considered intact. Interestingly we found that S771 which 
is a HKD mutant is lipase inactive. 
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Fig 27. Effect of DMSO on lipase activity. Most of the potent and specific PLD 
inhibitors are hydrophobic and soluble in organic solvents like DMSO. This figure shows 
the effect of increasing concentrations of DMSO on lipase activity. It is shown 
concentrations of DMSO up to 1% do not affect PLD activity. All the experiments with 
inhibitors are hence performed at safe levels of DMSO of 0.16%. 
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Fig 28. Effect of FIPI and NFOT on mutations in the PX region. All the mutants in 
the PX region that were screened for intact lipase activity were treated with 300 nM FIPI 
or NFOT to screen for a resistant mutant that could be the possible site of action. It was 
found that none of the mutations in the PX domain were resistant to inhibition by FIPI. 
But the mutants L126A, F129Y, Y165F, R172C and R172C/L173A were partially 
resistant to inhibition by NFOT.   
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Fig 29. Effect of FIPI and NFOT on mutations in the PH region. All the mutants in 
the PH were screened for intact lipase activity were treated with 300 nM FIPI or NFOT to 
screen for a resistant mutant that could be the possible site of action. R210A/R212A and 
F244N/L245A/L246A were found partially resistant to NFOT. 
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Fig 30. Effect of FIPI and NFOT on mutation in HKD region. All the mutants in the 
HKD were screened for intact lipase activity were treated with 300 nM FIPI or NFOT to 
screen for a resistant mutant that could be the possible site of action. S648A was resistant 
to NFOT and S757A was partially resistant to NFOT and FIPI.	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Fig 31. Effect of mutation in PX region on NFOT action. To confirm the results 
obtained earlier, the lipase activity of resistant PX mutants in the presence of a range of 
concentration of NFOT was measured. None of the PX mutants showed resistance to 
inhibition by NFOT. 
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Fig 32. Effect of mutation in PH region on NFOT action. To confirm the results 
obtained earlier, the lipase activity of R210A/R212A and F244N/L245A/L246A mutants 
in the PH region in the presence of a range of concentrations of NFOT was measured. It 
was found that R210A/R212A and F244N/L245A/L246A were partially resistant to 
inhibition by NFOT. 
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Fig 33. Effect of mutation in HKD region on NFOT action. To confirm the results 
obtained earlier, the lipase activity of S648A and S757A mutants in the HKD in the over 
a concentration range of NFOT was measured. It was found that S757A and S648A 
mutants were partially resistant to inhibition by NFOT. 
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Fig 34. Effect of mutation in HKD region on NFOT action in cell lysates. To confirm 
the results obtained earlier, the lipase activity of S648A in the HKD in the over a 
concentration range of NFOT was measured in cell lysates. It S648A was partially 
resistant to inhibition by NFOT. 
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Fig 35. Effect of mutation in PH region or HKD region on NFOT: quantification. 
The graph showing partial resistance was quantified and subject to paired t-test for 
showing statistical significance. The inhibition of WT was highly significant (P<0.005), 
while that of the triple mutant and S648A was not significant.  
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Fig 36. Chemotaxis of intact PX, PH and HKD mutants. To test for the biological 
relevance of these mutations, the mutants were tested for their chemotactic ability. It was 
observed that many of the mutations showed similar chemotaxis respective to their 
activities.	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Fig 37. Effect of inhibitors FIPI and NFOT selected PLD mutations: Functional 
relevance. Some of the studies showed R210A/R212A, F244N/L245A/L24A, S648A and 
S757A are resistant to inhibition by NFOT. And S757A was partially resistant to 
inhibition by FIPI as well. In order to study the biological relevance, we studied the 
chemotaxis of these mutations and found that these mutants had intact chemotaxis with 
no inhibitor treatment and they are resistant to inhibition by NFOT but not by FIPI except 
S757A.	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Fig 38. Role of silencing Ras in PLD2 inhibition by NFOT. Silencing Ras increased 
PLD2 activity suggesting Ras could be negatively regulating PLD2 in the cells, but PLD2 
activity was inhibited upon treatment with inhibitors.	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Fig 39. Role of overexpressed Grb2 in PLD2 inhibition by FIPI and NFOT. As we 
already know that Grb2 positively regulates PLD activity, we wanted to look at the role 
of overexpressing Grb2 in inhibition of PLD activity by FIPI and NFOT. Overexpression 
of Grb2 showed an increase in PLD activity compared to mock transfected cells. Upon 
treatment with 300nM of inhibitors FIPI or NFOT, lipase activity of mock cells decreased 
rapidly, while the Grb2 overexpressed cells when treated with 300nM NFOT showed 
significant resistance (P<0.005), but when treated with 300nM FIPI PLD2 activity was 
inhibited.	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Fig 40. Western blot of silencing Ras. This is a western blot showing Ras silencing in 
COS7 cells. 
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Fig 41. Western blot of overexpressing PLD2 and Grb2. This is a western blot 
showing co-expression of PLD2 and Grb2 or PLD2 alone in COS7 cells. 
  
	   	   82	  
	   	   	   	  
	  
Fig 42. Model for Grb2 and Ras role in PLD2 inhibition. The model shows that NFOT 
binds to an allosteric site with high affinity and with comparatively low affinity to the 
catalytic site on PLD2 upon PLD2 interactions with Grb2. On the other hand, Ras has a 
negative effect on PLD2 activity. 
	  
	  	  
	   	  
	   	   83	  
	   	   	   	  
	  
	  
Fig 43. Summary model. This is a model of the study showing FIPI is an irreversible (or 
non-competitive inhibitor) and NFOT is a reversible (mixed inhibitor). The possible sites 
of action of NFOT are F244/245/246 or nearby in the PH region and S648 or nearby in 
the HKD region and the possible site of action of FIPI is S757 or nearby in the HKD 
region. Ras negatively regulates PLD2 and does not significantly affect the inhibition of 
PLD2. Grb2 positively regulates PLD2 by binding to PLD2, and affects the binding site 
of action of NFOT on PLD2 thus showing partial resistance to inhibition by NFOT, while 
FIPI on the other hand could possibly be modifying the protein irreversibly and hence the 
lipase activity is significantly inhibited. 	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